Thursday, November 19, 2026
News

Novo Nordisk says India is key to its sickle cell drug discovery programme

SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | November 19, 2026 7:11:31 PM IST
India plays a key role in Novo Nordisks drug discovery programme for sickle cell disease, the Danish pharmaceutical companys India Managing Director Vikrant Shrotriya said on Thursday. He said the company is also working with the Centre and state governments in districts where the disease affects tribal communities.

India is a very important part of that drug discovery program when it comes to sickle cell, Shrotriya told ANI on the sidelines of the Organisation of Pharmaceutical Producers of India (OPPI) Annual Summit on pharmaceutical innovation in New Delhi.

Shrotriya said the company has about three or four wellness centres in districts where tribal communities are affected by the disease. He also pointed to Indias goal of eliminating sickle cell anaemia as a public health problem by 2047.

The Novo Nordisk Education Foundation has signed an agreement with Rabindranath Tagore Medical College in Udaipur to set up a sickle cell wellness hub. According to the foundation, the hub is intended to help patients get diagnosed earlier, access care and receive regular monitoring, nutritional guidance and counselling. The partnership also aims to train healthcare workers in managing the disease.

The government launched the National Sickle Cell Anaemia Elimination Mission in 2023. The mission combines screening and early diagnosis with counselling, treatment and follow-up care. In a September update, the Ministry of Health and Family Welfare said more than 7.29 crore people had been screened under the mission, with about 2.5 lakh diagnosed with the disease and more than 20 lakh identified as carriers.

On AI, Shrotriya said the companys Global Business Services team in Bengaluru works with research data to help researchers get results faster. They are actually working nothing but data and the use of AI in drug discovery, he said.

Shrotriya described data as a critical part of drug development and said the organization is working relentlessly in terms of squeezing the time for the launches.

Novo Nordisk set up its Bengaluru Global Business Services centre in 2007. The centre supports more than 80 of the companys affiliates worldwide, according to its India website. Its work includes managing and analysing clinical trial data, preparing clinical reports and monitoring drug safety.

Globally, Novo Nordisk announced in September that it would work with Anthropic to apply AI to drug discovery problems identified by its scientists. In August, it announced a partnership with Amazon Web Services that includes a joint AI hub in London. The company said the hub aims to shorten the time between identifying a potential drug target and giving the first dose to a human participant. (ANI)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE BUSINESS NEWS
Globalizing Energy Socialism Mission Inn...
Vagdevi Vilas Institutions Launches New ...
From MoU to market: What India's univers...
Apple moves toward multiyear memory deal...
South Korea's exports cross USD 1 trilli...
SEBI Chairman calls for continuous train...
More...
 
INDIA WORLD ASIA
Gujarat Govt launches Operation Health...
Policy cannot come at the cost of citize...
'Schemes reached the very last edge of v...
'Case will be solved soon': SDPO Umeshwa...
Union Minister Bhupendra Yadav directs D...
Will not allow BJP a cakewalk to disman...
More...    
 
 Top Stories
Russia, China, US adopt "Declaratio... 
Chhattisgarh State Day to be celebr... 
Meta to launch India's first govern... 
"Was a pleasure spending time with ... 
CM Yogi slams SP over Gorakhpur chi... 
Panchayats spend 48% of water, sani... 
SEBI resolves 5,975 investor compla... 
Novo Nordisk says India is key to i...